Bilobalide modulates serotonin-controlled behaviors in the nematode Caenorhabditis elegans by Brown, Marishka K & Luo, Yuan
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Neuroscience
Open Access Research article
Bilobalide modulates serotonin-controlled behaviors in the 
nematode Caenorhabditis elegans
Marishka K Brown1 and Yuan Luo*1,2
Address: 1Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, USA and 2Center for integrative 
Medicine, School of Medicine, University of Maryland Baltimore, USA
Email: Marishka K Brown - mbrow004@umaryland.edu; Yuan Luo* - yluo@rx.umaryland.edu
* Corresponding author    
Abstract
Background:  Dysfunctions in the serotonergic system have been implicated in several
neurological disorders such as depression. Elderly individuals who have been diagnosed with clinical
depression show elevated cases of neurodegenerative diseases. This has led to suggestions that
modulating the serotonin (5-HT) system could provide an alternative method to current therapies
for alleviating these pathologies. The neuroprotective effects of bilobalide in vitro have been
documented. We aim to determine whether bilobalide affects the 5-HT system in the nematode C.
elegans. The wild type worms, as well as well-characterized 5-HT mutants, were fed with bilobalide
in a range of concentrations, and several 5-HT controlled behaviors were tested.
Results: We observed that bilobalide significantly inhibited 5-HT-controlled egg-laying behavior in
a dose-dependent manner, which was blocked in the 5-HT receptor mutants (ser-4, mod-1), but not
in the 5-HT transporter (mod-5) or synthesis (tph-1) mutants. Bilobalide also potentiated a 5-HT-
controlled, experience-dependent locomotory behavior, termed the enhanced slowing response in
the wild type animals. However, this effect was fully blocked in 5-HT receptor mod-1 and dopamine
defective cat-2 mutants, but only partially blocked in ser-4 mutants. We also demonstrated that
acetylcholine transmission was inhibited in a transgenic C. elegans strain that constitutively
expresses Ab, and bilobalide did not significantly affect this inhibition.
Conclusion: These results suggest that bilobalide may modulate specific 5-HT receptor subtypes,
which involves interplay with dopamine transmission. Additional studies for the function of
bilobalide in neurotransmitter systems could aid in our understanding of its neuroprotective
properties.
Background
Serotonin (5-HT) modulates several behaviors in both
vertebrate and invertebrate systems and plays an impor-
tant role in neuronal plasticity and survival. It has also
been associated with behavioral deficiencies seen in
Alzheimer's patients [1]. The serotonergic system is partic-
ularly interesting because of its interactions with many
other neurotransmitters systems, such as glutamate, ace-
tylcholine and GABA [2]. In AD, there are drastic
decreases in excitatory neurotransmitters, whilst the
inhibitory effects of 5-HT on these systems remains rela-
tively stable [3]. These findings have led to suggestions
that antagonizing 5-HT receptors, specifically the 5-HT1
receptor subtype, could provide an alternative or an
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adjunct, to current AD therapies. Previous research has
found that induced cholinergic and glutamatergic dys-
function [4] were both alleviated by treatment with 5-
HT1A antagonist WAY 100 635. Experimental evidence
also supports a role for 5-HT receptors in learning and
memory [2]. Administration of selective serotonin
reuptake inhibitors (SSRIs) was reported to stimulate hip-
pocampal neurogenesis in adult rats; and this increase is
modulated through different 5-HT receptor subtypes [5].
These studies strongly support physiological, pathophysi-
ological as well as therapeutic roles linking the serotoner-
gic system with cognitive processes.
In the process of identifying behavioral phenotypes of a
neuronal amyloid b (Ab) expressing Caenorhabditis elegans
strain, we discovered a change of sensitivity to serotonin
(5-hydroxytryptamine 5-HT), which was restored by feed-
ing the worms with the Ginkgo biloba extract EGb 761 and
some of it's constituents [6]. This result led us to hypoth-
esize that certain pharmacologically active constituents of
the extract are responsible for protecting the worms
against Ab toxicity; partially through modulation of 5-HT
transmission.
Bilobalide, a sesquiterpene trilactone that accounts for
approximately 3% of EGb 761 has been shown in many
cases to be neuroprotective; particularly in models of
acute neurodegeneration and Parkinson's disease. It has
been reported that bilobalide protects against glutamater-
gic excitotoxicity both in vitro and in vivo [7-9] by antago-
nizing GABA receptors [10]. Bilobalide has also been
shown to inhibit N-methyl-D-aspartate-induced activa-
tion of phospholipase A2 and its resultant phospholipid
breakdown [7]. In combination with its inhibition of
glutamate-induced death on rat cerebellar granule neu-
rons, this has led to suggestions that bilobalide may be
useful in the treatment of certain neurological disorders.
In addition to these results, a high dose of bilobalide (100
mM) was shown to reduce the release of excitatory neuro-
transmitters [11]. In the present study, we seek to test the
hypothesis that modulation of the 5-HT system by bilo-
balide may attribute to its neuroprotective properties.
In C. elegans, several behaviors are controlled by the 5-HT
system [12,13]. Similar to mammals, there are two major
classes of 5-HT receptors in C. elegans. Table 1 provides a
summation of the different C. elegans mutants and their
specific mechanisms and/or functions that were utilized
in this study. Comparisons are made between the C. ele-
gans mutants and their mammalian homologues. As illus-
trated in table 1, the mod-1 receptor encodes an ionotropic
5HT receptor [14]. Ser-1, ser-4, and ser-7 are members of
the metabotropic G-protein-coupled 5HT receptor super-
family [15-17]. Using the available 5-HT transmission
mutants (Table 1) and 5-HT controlled behavioral assays,
possible genetic targets of bilobalide were demonstrated
in the present study.
Results
1. Inhibition of 5-HT stimulated egg-laying behavior by 
bilobalide requires serotonin receptors mod-1 and ser-4
Egg-laying is one of several well-defined behaviors C. ele-
gans that are controlled by 5-HT. Exogenous levels of 5-HT
can stimulate egg-laying behavior, a response extremely
useful in identifying the action of drugs on specific neuro-
transmitter pathways [18,19]. To determine if bilobalide
alters 5-HT stimulated egg-laying, the wild type worms
(adult day 1, 30 each group) were fed with bilobalide (BB)
from L1 young larvae, followed by the egg-laying assay.
When several concentrations of BB ranging from 0.003 to
30 mM was administered to the worms, a dose-dependent
inhibition by BB was statistically significant at concentra-
tions of 0.03 and 0.3 mM (n = 3, p < 0.05 Fig 1A) suggest-
ing a specificity of this inhibition. However,
concentrations higher than 3 mM were not statistically dif-
ferent from the control (data not shown).
We then sought to identify where BB might disrupt sero-
tonergic neurotransmission. The tph-1 mutant has a dele-
tion in the 5-HT biosynthetic enzyme, tryptophan
hydroxylase. This mutant lacks any detectable 5-HT and
accumulates an excess amount of fertilized eggs [20],
although its egg-laying circuitry remains responsive to
exogenous 5-HT. The mod-5 mutant (Fig. 2) encodes for
the only serotonin reuptake transporter (SERT) that has
Table 1: C. elegans 5-HT mutants with respect to mammalian counterparts
C. elegans 5-HT mutants Mammalian homologues Gene product mechanisms Function in C. elegans
SER-4 5-HT1 receptors ¯  levels of cAMP Required for normal inhibition of movement by 
5-HT and stimulation of egg-laying by imipramine
SER-1 5-HT2 receptors  IP3, DAG, Ca2+ Required for the stimulation of egg-laying by 5-HT 
and weakly for pharyngeal pumping
MOD-5 SLC6A4 Na/Cl 5-HT transporter Required for stimulation of egg-laying in by 5-HT
TPH-1 Tph1 Tryptophan hydroxylase
MOD-1 GABAB3 5-HT-gated Cl channels Required for enhanced slowing response exhibited 
by food-deprived animals upon encountering a 
bacterial food sourceBMC Neuroscience 2009, 10:62 http://www.biomedcentral.com/1471-2202/10/62
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Serotonin stimulated egg-laying and survival assay Figure 1
Serotonin stimulated egg-laying and survival assay. (A) Wild type young larvae (L1) were fed with bilobalide (BB) rang-
ing from 3 nM to 3 mM for 4 days. The number of eggs was scored 60 minutes after 5-HT (5 mg/ml) was added in 96-well plates 
(*p < 0.05, **p < 0.001). (B) Egg-laying response to BB in wild type and 5-HT mutants adult day 1 worms. (C) Wild type adult 
day 1 worms (8 from each group) were fed with Bilobalide (BB) (0.3 mM) from L1 stage. Animals were then pre-incubated with 
dopamine for 2 h before being placed in a 5-HT solution. The bars represent the mean of the number of eggs from three indi-
vidual assays; *p < 0.05. (D) Life span assay in N2 C. elegans fed either Bilobalide (BB) 0.3 mM (closed circle, bilobalide), WAY 
100 635 (open squares, WAY 100 635) 0.3 mM or the vehicle control (open circle, Ctrl). Worms were transferred for 4 con-
secutive days during their egg-laying phase, and then every other day after the egg-laying phase was completed. Data are 
expressed as the percentage (%) of survival in an age-synchronized population. Three independent experiments were per-
formed with number of worms totaling 200.
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been discovered in C. elegans [21]. mod-1 encodes an iono-
tropic 5-HT receptor (5-HTR) [14] and SER-4 is a member
of metabotropic G-protein coupled receptors, similar to
mammalian 5-HT2 and 5-HT1A subtypes [16]. Both of
these receptor subtypes are expressed in the neurons.
When 5-HT stimulated egg-laying was scored in wild type
and four 5-HT system defective mutants (tph-1, mod-5,
mod-1 and ser-4) treated with BB, the inhibitory effect by
BB was blocked in mod-1 and ser-4 mutants. The tph-1 and
mod-5 mutants respond to BB in a similar manner as wild
type (Fig. 1B), which suggest that the presynaptic compo-
nent may not be required for the effect of BB on this par-
ticular behavior. These results indicate that the 5-HT
receptors (mod-1 and ser-4) (Fig. 2) may be necessary for
the BB effect in the egg-laying assay.
Since BB displayed inhibitory effects on 5-HT stimulated
egg-laying, we next sought to determine if it would inter-
act with a known inhibitor of egg-laying in C. elegans, the
neurotransmitter dopamine (DA) [19]. Various concen-
trations of BB failed to inhibit egg-laying in the cat-2 DA
mutant (data not shown). In wild type animals that were
pre-incubated with increasing concentrations of exoge-
nous DA, there was a dose-dependent inhibition of their
egg-laying behavior (Fig. 1C). Wild type worms that were
fed BB (0.3 mM) and then pre-treated with DA for 2 h
before 5-HT stimulated egg-laying assay did not show an
inhibition in egg-laying by DA (Fig. 1C). In fact, the egg-
laying response was similar to the response seen in the
wild type worms with no treatment at all (Ctrl. 100% ±
1.1, BB 62.7% ± 1.3 p < 0.05) (DA 3 mg/ml 92% ± 3.5, BB
50.3% ± 4.2) (DA 6 mg/ml 65.4% ± 4.1, BB 103% ± 3.2 p
< 0.05).
Since bilobalide had a significant effect on 5-HT-control-
led egg-laying, we wanted to determine whether it, or a
known 5-HT receptor antagonist WAY 100 635 (0.3 mM),
would have any impact on life span and to ensure that the
results seen with BB treatment were not a consequence of
toxicity. Neither BB (0.3 mM) nor WAY 100 635 signifi-
cantly affected the life span of wild type worms (Fig 1D,
BB: 13.76 ± 0.54; WAY 100 635:13.97 ± 0.6; control
group: 13.8 ± 0.31). This result excludes the possibility of
a general effect by bilobalide on the life span of C. elegans.
2. Bilobalide potentiates a 5HT controlled experience-
dependent locomotory behavior
We decided to utilize the basal and enhanced slowing
responses (BSR and ESR, illustrated in Fig. 3A), which are
measures of behavioral plasticity in the worms, to deter-
mine the effect of BB on an experience-dependant behav-
ior. The slowing responses are used to associate prior
Schematic diagram of the neurotransmitter controlled behaviors and the associated mutant used in this study Figure 2
Schematic diagram of the neurotransmitter controlled behaviors and the associated mutant used in this study. 
The CAT-2 gene encodes for tyrosine hydroxylase and is the primary pathway for dopamine (DA) synthesis. Serotonin synthe-
sis requires the TPH-1 tryptophan hydroxylase gene. Serotonin is removed from the synaptic space by the MOD-5 serotonin 
reuptake transporter. MOD-1 receptor encodes an ionotropic 5HT receptor and SER-4 belongs to the class of metabotropic 
G-protein-coupled 5HT receptors, and is homologous to mammalian 5-HT1 receptor class. The drug aldicarb is a cholineste-
rase inhibitor that causes an accumulation of acetylcholine at the neuromuscular junction, which eventually leads to paralysis. 
Exogenous 5-HT can inhibit this behavior. 5-HT stimulates egg-laying in C. elegans and both dopamine and acetylcholine 
inhibit it.
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feeding experience with response to food. This makes
these responses a type of associative learning behavior
(Fig. 3A). In the worms, the basal and enhanced slowing
responses are mediated by dopamine and serotonin,
respectively. Sawin et al. demonstrated that mod-1 mutant
worms were defective in the 5-HT controlled enhanced
slowing response. This group also reported that cat-2
(e1112) mutants that are deficient in the enzyme tyrosine
hydroxylase, which is required for the synthesis of
dopamine (DA), have normal serotonergic transmission
but are defective in the DA mediated basal slowing
response [12]. This same study also showed that when
these animals are pre-incubated with exogenous DA, the
basal slowing response is rescued. In the present study, we
show that feeding the worms 0.3 mM of BB for three days
before the assay significantly potentiated the ESR in wild
type worms (Fig. 3B). However, this enhancement by BB
was completely blocked in the mod-1 (Fig. 3C) and cat-2
(e1112) (Fig. 4C), p = 0.04, but not in ser-4 (Fig. 3E),
mutant animals. Previous studies have reported that defi-
ciencies in the serotonin receptors could lead to defects in
the enhanced slowing response [14]; although a mod-5
mutation leads to a hyper-enhanced slowing response
[21]. In the presents study, the ser-4 mutant animals did
not show any abnormalities in the ESR, although there
were slight changes in the BSR for both ser-4 and mod-1
(Fig. 4C&E). These results suggest that another mecha-
nism for the neuroprotective effects of BB may involve
altering the serotonergic as well as the dopaminergic sys-
tem.
3. Animals that constitutively express Ab show reduced 
aldicarb sensitivity
In the presence of the acetylcholinesterase inhibitor aldi-
carb, accumulation of acetylcholine (ACh) in the synapse
causes the worms to paralyze; which is inhibited by 5-HT
[22]. This assay was adapted to determine the impact of
Ab-expression on the interaction between 5-HT and ACh.
Wild type worms (Fig 4A. open circles) were exposed to 1
mM aldicarb and scored for progressive paralyses every 20
min. In Fig. 4A (filled circles), animals that were pre-incu-
bated with 5-HT show a decrease in aldicarb sensitivity.
Next, we compared the aldicarb sensitivity phenotype in
wild type (N2) and a C. elegans mutant that constitutively
expresses human amyloid beta in the muscle cells
(CL2006). The results show that Ab mutants (Fig. 4A,
open squares, CL2006) were more resistant to aldicarb
exposure than the wild type worms (open circles, N2, Fig.
4A) indicating a defect in ACh transmission in the Ab
strain. When Ab mutants were pre-incubated with 5-HT
(filled squares, CL2006 w/5-HT, Fig. 4A), their paralyses
were remarkably delayed compared with wild type worms
pre-incubated with 5-HT (filled circles N2 w/5-HT Fig.
4A) or the Ab mutants that were not pre-incubated with 5-
HT (open squares, CL2006). These results extend our pre-
vious findings [6] and suggest that Ab expression alters
both 5-HT as well as ACh transmission in C. elegans.
We next wanted to elucidate whether BB modulates Ab-
reduced aldicarb sensitivity. The mutant worms were fed
BB (0.3 mM) for 4 days and then pre-incubated for 2 hrs
on 1 mM of 5-HT followed by the aldicarb paralysis assay.
Interestingly, the Ab worms fed with BB (0.3 mM open
squares, control Fig. 4B) did not rescue the impairment
compared with non-treated controls (filled squares, con-
trol (Fig. 4B), indicating that BB is not specific to Ach
transmission as well as its associated effect by Ab expres-
sion.
Discussion
Serotonin has been shown to modulate many different
behaviors in the nematode C. elegans. In the present study,
we demonstrate a novel mechanism by which bilobalide
(BB) modulates behavioral plasticity in C. elegans by
antagonistically regulating serotonergic receptors. BB
antagonizes egg-laying behavior via modulation of iono-
tropic MOD-1 and metabotropic SER-4 receptors in C. ele-
gans, which are homologues to mammalian GABA-gated
chloride channels and 5-HT1A/5-HT2A receptors, respec-
tively. In addition, we demonstrated that Ab expression in
the worms reduced their sensitivity to aldicarb, an acetyl-
cholinesterase inhibitor (AChEI). However, BB did not
affect this behavior. Our results suggest that modulation
of the 5-HT system by BB partially underlies its neuropro-
tective and efficacious effects in several in vitro systems [8-
11]. Recent studies revealed a role of 5-HT receptors (5-
HTR) in controlling C. elegans life span [23]. A mutation
in the ser-1 gene, which encodes a 5-HT2-like receptor
[16], dramatically increased life span (by 46%) and signif-
icantly enhanced thermotolerance and UV resistance in
the worms [13]. These finding may provide an explana-
tion for our previous data that EGb 761 extends life span
[24]; an effect that could be partially due to bilobalide
modulation of the 5-HT system. Supporting this view,
another independent study that screened 88,000 com-
pounds for life span extension in C. elegans found that the
most potent life span extending compounds are antide-
pressant drugs that are antagonists of 5HT2A receptors in
humans [25]. Despite unfavorable outcome from clinical
studies of EGb 761[26], the unique features of its constit-
uents warrant future investigation [6].
The egg-laying assay in C. elegans has long served as a
behavioral marker for serotonergic neurotransmission. In
the present study, application of exogenous 5-HT stimu-
lated egg-laying in wild type C. elegans [27], which was sig-
nificantly inhibited in worms fed BB (Fig 1A). In tph-1
mutants, which are deficient in tryptophan hydroxylase,
an enzyme essential for synthesis of 5-HT [20], BB was
still able to inhibit 5-HT stimulated egg-laying. The inhi-BMC Neuroscience 2009, 10:62 http://www.biomedcentral.com/1471-2202/10/62
Page 6 of 10
(page number not for citation purposes)
Serotonin-controlled learning behavioral Figure 3
Serotonin-controlled learning behavioral. A. Schematic diagram of Slowing Responses in C. elegans. The basal and 
enhanced slowing responses (BSR), which are mediated by dopamine and serotonin, respectively are used to associate previ-
ous feeding experience. For the basal slowing response worms are well fed up until they are assayed. For the enhanced slowing 
response (ESR), there is a 30 min starvation period before they are assayed. (B) Basal (BSR) and enhanced (ESR) slowing 
responses in wild type animals fed with control or bilobalide (BB). (C) BSR and ESR in the mod-1 mutant worms fed with vehi-
cle control or treated with BB. (D) BSR and ESR in the cat-2 mutant worms control or treated with BB. Four separate trials 
were performed for each strain. Error Bars represent the standard error; asterisk; p < 0.05, Student's t test. (E) BSR and ESR 
in the ser-4 mutant worms fed with vehicle control or with BB.
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bition of egg-laying behavior by BB was blocked in mod-1
and ser-4, two 5-HTR mutants (Fig 1B), suggesting that
these receptors are required for BB activity in C. elegans 5-
HT-stimulated egg-laying behavior. Another possibility is
that BB inadvertently affects 5-HTR by effecting dopamine
(DA) function. Extensive research performed in rats, has
demonstrated that DA can be enhanced or diminished by
compounds that interact with specific 5-HTR subtypes
[19]. It has been reported that a mutation in MOD-1,
which is a 5-HT-gated ion channel similar to mammalian
GABA-Glycine-chloride channels, blocks DA inhibition of
egg-laying in C. elegans. Previous studies have demon-
strated that BB antagonizes GABA and glycine receptors in
embryonic cortical slices [28] and it binds GABAA recep-
tors at therapeutically relevant concentrations [10]. Antag-
onizing 5-HT receptor SER-4 by BB in C. elegans implicates
possible beneficial effects in learning and memory. 5-
HT1A receptor in mammals is structurally homologues to
the SER-4 receptors in C. elegans. In the mammalian sys-
tem, activation of 5-HT1A receptors causes defects in learn-
ing and memory. On the other hand, activation of the 5-
HT2A and 5-HT2C receptors facilitates the formation of
memory [2].
Although exogenous 5-HT stimulates egg-laying, it has an
inhibitory effect on locomotion [14]. 5-HT reduces loco-
motion rates by inhibiting the release of ACh at the C. ele-
gans neuromuscular junction [22]. This in turn, leads to
resistance to the cholinesterase inhibitor aldicarb, shown
as reduced paralysis in the worms exposed to aldicarb. For
the first time, we observed that a transgenic C. elegans
strain that constitutively expresses human Ab in the mus-
cle cells (CL2006) was resistant to aldicarb (Fig. 4A). Pre-
vious reports demonstrated that worms treated with 5-HT
receptor antagonist ketanserin and methiothepin became
hypersensitive to aldicarb, whereas DA receptor antago-
nist had no effect [22]. It should be noted that modula-
tion of 5-HT receptors in mammals is subtype and
synaptic localization dependent. Activation of 5-HT1A het-
eroreceptors resulted in a decrease in ACh release [29] and
impairment of cognitive functions [30], whereas, activa-
tion 5-HT1A autoreceptors can enhance cognition [31].
The restoration of the basal slowing response by BB in the
cat-2 mutants was surprising. Although the cat-2 mutants
are deficient in tyrosine hydroxylase, the enzyme needed
for DA synthesis, it has been shown that DA synthesis can
occur through alternative routes and that these worms still
have some functioning DA [32], although significantly
less than wild type. These results suggest that BB can mod-
ulate the interplay between the serotonergic and
dopaminergic systems, which is believed to a basic mech-
anism for synaptic plasticity in the worms [33]. Antago-
nist of 5-HTR subtypes appear to enhance activation and
signaling of neurotransmitter systems that are known to
be involved in cognition [34].
It is important to separate the effects of 5-HT on egg-lay-
ing and locomotion [35,36]. While application of exoge-
nous 5-HT stimulates egg-laying [27] it inhibits
locomotion [14]. In C. elegans egg-laying circuitry, there
are at least three separate responses to 5-HT [37]. Potential
interactions of different receptors subtypes [38] could also
account for the effects that are seen with BB. MOD-1 and
SER-4 have been shown to provide inhibitory input into
the egg-laying process [19,37] and ser-4; mod-1 double
Aldicarb Sensitivity Assay Figure 4
Aldicarb Sensitivity Assay. (A) Wild type (wt) or worms 
that constitutively express human amyloid beta in the muscle 
cells (CL2006) were pre-incubated for 2 hours on plates with 
or without 2 mM of 5-HT. Ab worms (CL2006), exhibit a 
natural resistance to aldicarb, in comparison to wild type 
controls. Each group contained 30 animals that were placed 
on 1 mM of aldicarb and scored until death. (B) Ab worms 
(CL2006) were fed BB (0.3 mM) then pre-treated with 2 mM 
of exogenous 5-HT for 2 hrs. BB treatment has no effect on 
aldicarb sensitivity in transgenic Ab worms (CL2006) pre-
exposed to 5-HT. Data was obtained from three independ-
ent experiments. Each group consisted of 30 worms.
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mutants actually lay more eggs than wild type animals in
the 5-HT stimulated egg-laying assay [38]. It is also impor-
tant to note that stimulation of egg-laying by 5-HT occurs
via receptors expressed in the muscles and inhibition
occurs via receptors located in the neurons [37]. Since
many of the mechanisms of BB remain unclear, it is pos-
sible that its modulation of these behaviors is location
specific. So, inhibition of egg-laying behavior and the
potentiation of the locomotory behaviors are not neces-
sarily contradictory.
Several studies have demonstrated that antagonism of 5-
HT1A receptors is beneficial in cognitive processes. WAY
100635 and NAD-299 (robalzotan) two selective 5-HT1A
receptor antagonist, were able to attenuate the impair-
ments in passive avoidance behavior in rats elicited by
scopolamine [34]. Also, a new 5-HT1A receptor antagonist,
WAY 101405 was able to reverse cognitive impairments
caused by scopolamine, in both the novel object recogni-
tion and contextual fear condition paradigms in rats [39].
Lecozotan, a 5-HT1A antagonist that has completed phase
I clinical trials, was shown to potentiate the stimulated
release of glutamate and acetylcholine in the hippocam-
pus [40]. Although we demonstrated in this study that BB
can interact with both serotonergic and dopaminergic sig-
naling in C. elegans, its role may be more important in
neuroprotection than disease alleviation since there were
no observed effects on Ab toxicity.
In conclusion, bilobalide modulates interplay of 5-HT
and dopamine neurotransmission systems. Additional
studies for the function of bilobalide in neurotransmitter
systems would further our understanding of its neuropro-
tective properties.
Methods
Materials
Bilobalide (BB), serotonin creatinine sulfate complex (5-
HT), dopamine hydrochloride (DA) and aldicarb were all
purchased from Sigma (St. Louis, MO). Stock solutions of
all chemicals were made either with 95% ethanol, M9
Buffer or distilled water. The final concentration of etha-
nol, when dissolved in the food (Escherichia coli strain
OP50) did not exceed 0.01%. All chemicals/drugs for
treatment of experimental animals were added directly to
the OP50 food source.
C. elegans strains
mod-1 (ok103), ser-4(C. elegans Gene Knockout Consor-
tium), tph-1 (mg280), mod-5(n3314), cat-2(e1112) and
N2 (Bristol) were all obtained from the Caenorhabditis
Genetics Center, University of Minnesota. The transgenic
strain CL2006 has the unc-54/Ab1–42 and rol-6 (su1066)
transgenes integrated into the worm's chromosome and it
constituently expresses Ab1–42 in the muscle cells [41].
CL2006 was a gift from Dr. CD Link from the University
of Colorado-Boulder. All animals were grown on solid
nematode growth media (NGM), with 100 ml OP50 con-
taining either vehicles or chemicals, at 20°C from egg or
L1 (day 1 young larvae) until assayed, unless stated other-
wise.
C. elegans maintenance and treatment
All animals were cultured at 20°C under standard labora-
tory conditions. To age synchronize animals, adult nema-
todes were transferred to fresh NGM plates and allowed to
lay eggs for 2–4 h. Isolated hatchlings from the synchro-
nized day 1 young larvae (L1), were cultured on fresh
NGM plates in a 20°C temperature-controlled incubator
(model 2005; Sheldon Manufacturing, Cornelius, OR).
The worms were fed the drugs either from stage L1 (1 d of
age) or starting from the egg.
Behavioral Studies
Egg-laying Assay
The average number of eggs released per hour was quanti-
fied according to a well established assay [18,19,27],
except animals were assayed ~40 ± 2 h after the L4 young
larvae stage, so that animals could be fed the drugs for a
full three days. Age-synchronized well-fed L4 young larvae
were transferred to fresh plates seeded with OP50 contain-
ing either vehicle or Bilobalide and allowed to develop for
~20 ± 2 h at 20°C. After another 20 h, the resultant young
adults were assayed for their response to the drugs. Indi-
vidual young adults were transferred to a 96-well plate
containing 100 ml of a 5 mg/ml solution of serotonin cre-
atinine sulfate complex dissolved in M9. The number of
eggs released at room temperature was scored after 60
min.
Life span Assay
The life span assay was performed as described previously
[42]. Age synchronized animals were fed with 0.3 mM of
Bilobalide from L4 and maintained at 20°C. Animals
were transferred daily for 4 consecutive days until they
ceased to lay eggs to avoid overlapping generations.
Worms were scored as dead if they did not respond to a
touch stimulus by a platinum loop.
Aldicarb Sensitivity Assay
The acetylcholinesterase inhibitor aldicarb, results in a
toxic accumulation of acetylcholine (ACh) in the neu-
romuscular junction. Aldicarb sensitivity was assayed in
adult day 1 animals by analyzing the onset of paralysis
following treatment with 1 mM aldicarb. Animals were
prodded every 20 min with a platinum wire loop follow-
ing exposure to drug. As indicated, some worms were pre-
incubated with 5-HT for 2 h prior to the assay. Worms
were non-treated or fed with BB (0.3 mM), starting from
the egg.BMC Neuroscience 2009, 10:62 http://www.biomedcentral.com/1471-2202/10/62
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Locomotory Rate Assays
Assays were performed according to Sawin et al (Sawin,
2000) with slight modifications. A ring of E. coli strain
OP50 was placed on a 5 cm Petri plate containing NGM.
Assay plates were freshly spread with bacteria and allowed
to incubate at room temperature overnight. Age synchro-
nized young adult hermaphrodites (~20 ± 2 hrs after L4
larval stage) were tested. For the well-fed animals, we
measured the locomotory rate by removing 5 animals
from bacteria-containing plates and washing the animals
three times in S basal buffer, and then quickly transferring
them to an assay plate. Any buffer that remained on the
plates was absorbed with a Kimwipe. Five minutes after
the worms were transferred; we measured the number of
body bends in 30 second intervals for each of the 5 ani-
mals that were on the assay plate. The angle of a body
bend is typically more than 90°.
For the starved animals, 5–10 animals were washed free of
bacteria in S basal buffer (3X's) and then transferred to a
5 cm NGM agar plate that was free of bacteria. Excess
buffer was removed with a Kimwipe. The animals were
incubated on these plates for 30 minutes at room temper-
ature. After 30 minutes of starvation, five worms were
transferred to assay plates and the locomotory rate was
measured as described above.
Neurotransmitter Pre-treatment
Solutions of dopamine hydrochloride (50 mM) were pre-
pared in M9 buffer and 400 ml of the solution or M9 was
added to each 5 cm plate containing ~10 ml of agar and a
bacterial lawn so that the final concentration of DA solu-
tion would be ~2 mM. The plates were allowed to dry at 1
hr at room temperature and then 40–50 worms (treated
and untreated were transferred to each plate. Animals
were incubated for 2 hrs at 20°C and then assayed accord-
ing to the locomotory assay mentioned above [12].
Data Analysis
Data are analyzed for statistical significance by independ-
ent Student's t test of untreated and drug-treated animal
groups using Origin 6.0 software (Microcal Software,
Northampton, MA). In all cases a value of p < 0.05 indi-
cates a significant difference.
Abbreviations used
AD: Alzheimer's disease; BB: bilobalide; 5-HT: serotonin;
DA: dopamine; 5-HTR: serotonin receptors; Ab: amyloid
beta peptide; BSR: basal slowing response; ESR: enhanced
slowing response.
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